AI filing briefs · archive
Every 8-K brief, with filters
The whole archive: 33,547 AI briefs of material SEC Form 8-K filings by 4,788 companies: 2,161 written within three weeks of the filing (filed since Oct 19, 2026) and 31,386 written later, for past filings. Pick a month, or filter by date, 8-K item, tone, impact, topic or ticker.
Briefs on record33,547every one kept
Companies4,788with at least one brief
Recent filings2,161filed since Oct 19, 2026
Past filings31,386written later, in Nov 2026
Babcock & Wilcox reported third quarter 2026 revenue of $290.8 million, up from $139.2 million a year earlier, and net income of $93.9 million, up from $35.1 million. Net income was lifted by an $85.1 million change in the fair value of customer warrants, and adjusted net income was $4.8 million. The company reiterated its 2026 Adjusted EBITDA target of $80.0 million to $105.0 million and issued a 2027 Adjusted EBITDA target of $125 million to $140 million.
- Q3 2026 revenue of $290.8 million vs. $139.2 million in Q3 2025; Adjusted EBITDA of $17.7 million vs. $9.4 million
- Net income of $93.9 million includes an $85.1 million change in fair value of customer warrants; adjusted net income was $4.8 million
- Basic EPS of $0.61 vs. $0.30 in Q3 2025; Q3 bookings of $228 million and backlog of $2.5 billion
- 2026 Adjusted EBITDA target of $80.0 million to $105.0 million reiterated; 2027 target of $125 million to $140 million issued
Read the filing on SEC.gov ↗
Clearway Energy reported third-quarter 2026 revenue of $522 million, up from $429 million a year earlier, and net income of $123 million, up from $60 million. The company reaffirmed its 2026 CAFD guidance of $430 million to $470 million and set a 2027 CAFD guidance range of $520 million to $590 million. Net income attributable to Clearway Energy, Inc. fell to $51 million from $232 million, so shareholder-level earnings were lower.
- Q3 2026 revenue $522 million vs. $429 million in Q3 2025; Adjusted EBITDA $435 million vs. $385 million
- Net income attributable to Clearway Energy, Inc. was $51 million ($0.42 per share) vs. $232 million ($1.97 per share) a year earlier
- 2026 CAFD guidance reaffirmed at $430 million to $470 million; 2027 CAFD guidance set at $520 million to $590 million
- Board declared a quarterly dividend of $0.4824 per share payable December 15, 2026, to holders of record as of December 1, 2026
Read the filing on SEC.gov ↗
Qualys reported third-quarter 2026 revenue of $188.0 million, up 11% from $169.9 million a year earlier, and GAAP diluted earnings of $1.62 per share versus $1.39. The company raised its full-year 2026 revenue guidance to $736.9 million-$738.9 million from $732.0 million-$738.0 million and its GAAP EPS guidance to $6.08-$6.15 from $5.76-$5.90, which points to a higher outlook for shareholders.
- Q3 revenue $188.0 million, up 11% from $169.9 million; GAAP net income $57.2 million
- GAAP diluted EPS $1.62 vs. $1.39; non-GAAP diluted EPS $2.12 vs. $1.86
- Full-year 2026 revenue guidance raised to $736.9 million-$738.9 million; GAAP EPS guidance raised to $6.08-$6.15
- Q4 2026 revenue guidance set at $191.0 million-$193.0 million, 9% to 10% growth
Read the filing on SEC.gov ↗
Onto Innovation reported fiscal third-quarter 2026 revenue of $409.7 million, up 87.8% from a year earlier, with GAAP net income of $46.8 million, or $0.95 diluted EPS, versus $0.57 a year earlier. The company also guided fourth-quarter 2026 revenue to $430 million to $450 million and non-GAAP diluted EPS to $2.59 to $2.79, while a $40.8 million unrealized loss on its Rigaku investment weighed on GAAP results.
- Q3 revenue of $409.7 million vs. $218.2 million in Q3 2025; non-GAAP diluted EPS of $2.44 vs. $0.92
- GAAP net income of $46.8 million includes a $40.8 million unrealized loss on the Rigaku investment
- Q4 2026 guidance: revenue of $430 million to $450 million; GAAP diluted EPS of $1.95 to $2.07
- Cash, equivalents and marketable securities of $1.25 billion at September 30, 2026; backlog above $1.3 billion
Read the filing on SEC.gov ↗
Sanmina reported unaudited fourth-quarter fiscal 2026 results for the quarter ended October 3, 2026, with revenue of $3.86 billion, GAAP diluted EPS of $2.14 versus $0.88 a year earlier, and gave fiscal 2027 revenue guidance of $17.5 billion to $19.5 billion. The company also disclosed Amendment No. 5 to its credit agreement, which adds $70 million of term A loans and extends key debt maturities to October 28, 2031.
- Q4 revenue $3.86 billion vs $2.10 billion a year earlier; GAAP diluted EPS $2.14 vs $0.88; non-GAAP diluted EPS $4.43 vs $1.67
- Q1 fiscal 2027 outlook: revenue $3.8 billion to $4.1 billion; non-GAAP diluted EPS $3.50 to $3.85
- Fiscal 2027 outlook: revenue $17.5 billion to $19.5 billion; non-GAAP diluted EPS $15.50 to $17.50
- Amendment No. 5 dated October 27, 2026 adds $70 million of term A-1 loans, returns the term loan A facility to $1.4 billion, and extends the $1.5 billion revolver to October 28, 2031
Read the filing on SEC.gov ↗
Marygold Companies reported results for the fiscal first quarter ended September 30, 2026. Revenue rose to $9.4 million from $5.2 million a year earlier, and net income was $1.8 million, or $0.04 per share, compared with a net loss of $0.4 million, or $0.01 per share. The company also disclosed a pending definitive merger agreement under which funds managed by Madison Dearborn Partners would acquire all outstanding shares for $2.00 per share.
- Revenue of $9.4 million for the quarter, up from $5.2 million a year earlier, excluding $1.5 million from discontinued New Zealand operations
- Net income of $1.8 million, or $0.04 per share, versus a net loss of $0.4 million, or $0.01 per share, a year earlier
- USCF Investments average assets under management rose to $5.5 billion from $2.9 billion a year earlier
- Pending merger at $2.00 per share by Madison Dearborn Partners, expected to close in the first half of 2027 or earlier
Read the filing on SEC.gov ↗
KALA BIO reported preliminary, unaudited results for the quarter ended September 30, 2026, showing a net loss of approximately $0.8 million, down from $7.6 million a year earlier. Cash, cash equivalents and short-term investments were approximately $7.0 million with no debt, and the company expects to file its Form 10-Q on or about November 16, 2026. Final results may differ from these preliminary figures, which shareholders should weigh against the pending review.
- Q3 2026 net loss of approximately $0.8 million vs. $7.6 million in Q3 2025
- Nine-month 2026 net loss of approximately $4.0 million vs. $27.7 million in the same period of 2025
- Cash, cash equivalents and short-term investments of approximately $7.0 million as of September 30, 2026, with no debt
- Form 10-Q expected on or about November 16, 2026; results remain preliminary and unaudited
Read the filing on SEC.gov ↗
Telos Corporation reported third quarter 2026 revenue of $55.2 million, up from $51.4 million a year earlier, and GAAP net income of $4.4 million, or $0.06 per diluted share, compared with a net loss of $2.1 million a year earlier. The company also raised its full-year 2026 revenue and adjusted EBITDA outlook, which points to stronger results for shareholders.
- Q3 2026 revenue was $55.2 million, versus $51.4 million in Q3 2025.
- GAAP net income was $4.4 million ($0.06 per diluted share), compared with a net loss of $2.1 million ($0.03 per share) a year earlier.
- Full-year 2026 revenue outlook was raised to $198.2 million-$200.7 million from $187 million-$195 million.
- Full-year 2026 adjusted EBITDA outlook was raised to $32.3 million-$34.1 million from $23.6 million-$28.6 million.
Read the filing on SEC.gov ↗
United-Guardian reported higher third-quarter 2026 results, with net sales up 54% to $3,494,780 and net income up 247% to $930,912, or $0.20 per share. For the first nine months, net sales rose 25% to $9,475,269 and net income rose 70% to $2,478,393, or $0.54 per share, showing growth in both periods for shareholders.
- Q3 2026 net sales were $3,494,780, up 54% from $2,264,261 in Q3 2025.
- Q3 2026 net income was $930,912 ($0.20 per share), up 247% from $268,441 ($0.06 per share).
- Nine-month 2026 net sales were $9,475,269, up 25%; net income was $2,478,393 ($0.54 per share), up 70%.
- Pharmaceutical sales grew 29% in the quarter, driven primarily by Renacidin; cosmetic ingredient sales rose 187%.
Read the filing on SEC.gov ↗
Mereo BioPharma reported a third-quarter 2026 net loss of $5.9 million, down from $7.0 million a year earlier, as research and development and general and administrative expenses fell and the company recorded $800 thousand of revenue versus none a year earlier. Cash and cash equivalents were $26.1 million at September 30, 2026, which the company says should fund operations into late 2027, excluding any potential option payments from Sentynl Therapeutics.
- Q3 2026 net loss was $5.9 million, compared with $7.0 million in Q3 2025; nine-month net loss was $19.6 million versus $34.5 million a year earlier.
- Q3 2026 revenue was $800 thousand, compared with no revenue in Q3 2025; R&D expenses fell to $2.1 million from $4.3 million and G&A expenses fell to $4.9 million from $6.0 million.
- Cash and cash equivalents were $26.1 million at September 30, 2026, down from $41.0 million at December 31, 2025.
- Sentynl's exercise of its alvelestat option would bring $40 million in upfront and R&D payments; Mereo expects to provide an FDA-related update before the end of 2026.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.